CEFEPIME MECANISMO DE ACCION PDF

uso se autoriza en el año y al igual que el Meropenem es estable ante la acción de las DHP MECANISMO DE. ACCIÓN. Los carbapenémicos al igual. was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam. Cefepima, clorhidrato de. Cefixima .. latura intestinal, un efecto que podría ser secundario a su acción de la función renal debido a su acción hipotensora.

Author: Zum Zolom
Country: Italy
Language: English (Spanish)
Genre: Photos
Published (Last): 9 March 2008
Pages: 415
PDF File Size: 15.93 Mb
ePub File Size: 19.78 Mb
ISBN: 939-3-46018-710-2
Downloads: 78007
Price: Free* [*Free Regsitration Required]
Uploader: Bajind

Metformin is a biguanide antihyperglycemic agent used for treating non-insulin-dependent diabetes mellitus NIDDM. It improves glycemic control by decreasing hepatic glucose production, as well as decreasing glucose absorption and increasing insulin-mediated glucose uptake. Another well-known benefit of this drug is modest weight loss. Mwcanismo is the drug of choice for obese NIDDM non-insulin dependent diabetes mellitus patients [ 12 ].

Metformin was approved in Canada initially in [ 8 ]the s in Europe, and in in the USA [ 13 ]. For use as an adjunct to diet and exercise in adult patients 18 years and older with non-insulin dependent diabetes mellitus. Metformin may also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome PCOS. Metformin may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults [ Label ].

Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike cefepimme, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects except in special circumstances and does not cause hyperinsulinemia.

With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease [ Label ]. Metformin’s mechanisms of action are unique from other classes of oral antihyperglycemic drugs.

Metformin decreases blood glucose levels by decreasing hepatic glucose production gluconeogenesisdecreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization [ Label ].

It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism [ 6 ][ 11 ]. Findings of recent studies [ 7 ][ 10 ][ 11 ] however, show that metformin, at clinically relevant plasma concentrations, inhibits hepatic gluconeogenesis in a redox-dependent manner independently mecaniemo reduction in citrate synthase flux, liver nucleotide concentrations, acetyl-CoA carboxylase enzyme activity, or gluconeogenic enzyme protein expression.

Studies show that clinically relevant concentrations of plasma metformin attained by acute intravenous, acute intraportal or chronic oral administration mecanizmo awake healthy meanismo diabetic rats inhibit gluconeogenesis from lactate and glycerol, but not from pyruvate and alanine, implying an increased cytosolic ccefepime state in mediating metformin’s glucose-lowering effects [ 7 ].

These effects have occurred independently of complex I inhibition [ 11 ][ 7 ]demonstrated by unaltered hepatic energy charge and citrate synthase flux. Normalizing the cytosolic redox state by infusion of methylene blue or dr contributing to gluconeogenesis independently of the cytosolic redox state stopped metformin-mediated inhibition of gluconeogenesis in vivo [ 9 ]. In mice expressing constitutively active acetyl-CoA carboxylase, metformin acutely reduced hepatic glucose production and increased the hepatic cytosolic redox state without altering hepatic triglyceride content or gluconeogenic enzyme expression [ 10 ].

Previous studies indicate that the glucose-lowering effects of metformin are mediated by the activation by metformin of AMP-activated protein kinase AMPK d, a liver enzyme which plays an important role in insulin signaling, energy balance, and the metabolism of both glucose and lipids. The activation of AMPK is thought to be necessary for metformin’s inhibitory effect on the production of glucose by liver cells.

Increased acicon utilization of glucose may be due to improved insulin binding to insulin receptors.

cefepime mecanismo de accion pdf

Metformin administration also increases AMPK activity in skeletal muscle. AMPK is known to trigger GLUT4 transporter deployment to the plasma membrane, resulting in insulin-independent glucose uptake [ 6 ][ 11 ].

  2N5458 DATASHEET PDF

The mechanism of action of metformin cefepije been under extensive study in recent years, and research is ongoing [ 9 ][ 7 ][ 10 ][ 11 ]. Studies using single oral doses of metformin to mg, and to mg, show that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. The clinical relevance of these decreases is unknown [ Label ].

Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism no metabolites have been identified in humans nor biliary excretion [ Label ]. Renal clearance is about 3. Acute oral toxicity LD The most common adverse effects of metformin include: Diarrhea, drowsiness, weakness, dizziness, malaise, and headache may also occur.

Metformin decreases liver uptake of lactate, thereby increasing lactate blood levels fe may increase the risk of lactic acidosis [ Label ].

There have been reported postmarketing cases of metformin-associated lactic acidosis, including some fatal cases. Such cases had a subtle onset and were accompanied by nonspecific symptoms including malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence.

In certain cases, hypotension and resistant bradyarrhythmias have occurred with severe lactic acidosis [ Label ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs e. In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [ Label ]. Lower doses should be used in the elderly and those with decreased renal function.

cefepime mecanismo de accion pdf – PDF Files

Metformin decreases fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin HbA1c levels, which are reflective of the last weeks of glucose control. Metformin may also have a positive effect on lipid levels. When used alone, metformin does not cause hypoglycemia, however, it may potentiate the hypoglycemic effects of sulfonylureas and insulin when they are used concomitantly. Patent US, issued October, Metformin Targets 1 Transporters 6 Biointeractions 8.

Abacavir Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level. Abaloparatide The therapeutic efficacy of Metformin can be decreased when used in combination with Abaloparatide.

Abemaciclib The excretion of Abemaciclib can be decreased when combined with Metformin. Acarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Metformin. Aceclofenac Aceclofenac may decrease the excretion rate of Metformin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Metformin which could result in a higher serum level.

Acetaminophen Acetaminophen may decrease the excretion rate of Metformin which could result in a higher serum level. Acetazolamide The risk or severity of lactic acidosis can be increased when Acetazolamide is combined with Metformin. Acetohexamide The risk or severity of hypoglycemia can be increased when Metformin is combined with Acetohexamide.

Acetyl sulfisoxazole The therapeutic efficacy of Metformin can be increased when used in combination with Acetyl sulfisoxazole. Acetylsalicylic acid Acetylsalicylic acid may increase the hypoglycemic activities of Metformin. Aclidinium Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Metformin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Acyclovir Acyclovir may decrease the excretion rate of Metformin which could result in a higher serum level. Adefovir Adefovir may decrease the excretion rate of Metformin which could result in a higher serum level.

Adefovir Dipivoxil Adefovir Dipivoxil may decrease the excretion rate of Metformin which could result in a higher serum level. Agmatine The serum concentration of Agmatine can be increased when it is combined with Metformin. Alaproclate The risk or severity of hypoglycemia can be increased when Alaproclate is combined with Metformin.

  E1CB ELIMINATION REACTION PDF

Albiglutide The risk or severity of hypoglycemia can be increased when Metformin is combined with Albiglutide. Albutrepenonacog alfa Metformin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Alclofenac Alclofenac may decrease the excretion rate of Metformin which could result in a higher serum level. Aldesleukin Aldesleukin may decrease the excretion rate of Metformin which could result in a higher serum level. Allopurinol Metformin may decrease the excretion rate of Allopurinol which could result in a higher serum level.

Allylestrenol Metformin may decrease the excretion rate of Allylestrenol which could result in a higher serum level. Almasilate Metformin may decrease the excretion rate of Almasilate which could result in a higher serum level. Alminoprofen Alminoprofen may decrease the excretion jecanismo of Metformin which could result in a higher serum level.

Almotriptan Metformin may decrease the excretion rate of Almotriptan which could result in a higher serum level. Aloxiprin Aloxiprin may increase the hypoglycemic activities of Metformin. Alprazolam Metformin may decrease the excretion rate of Alprazolam which could result in a higher serum level.

Amantadine The serum concentration of Metformin can be increased when it is combined with Amantadine. Amifampridine The serum concentration of Amifampridine can be increased when it is combined with ,ecanismo.

Amikacin Amikacin may decrease the excretion rate of Metformin which could result in a higher serum level. Amiloride The serum concentration of Metformin can be increased when it is combined with Amiloride. Amineptine Amineptine may decrease the hypoglycemic activities of Metformin.

Aminohippuric acid The serum concentration of Metformin can be increased when it is combined with Aminohippuric mecansimo. Aminophenazone Aminophenazone may decrease the excretion rate of Metformin which could result in a higher serum level. Aminosalicylic Acid Aminosalicylic Acid may increase the hypoglycemic activities of Metformin.

Amiodarone The serum concentration of Metformin can be increased when it is combined with Amiodarone. Amitriptyline Metformin may decrease the excretion rate of Defepime which could result in a higher serum level. Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Metformin. Amlodipine Metformin may decrease the excretion rate of Amlodipine which could result in a higher serum level.

Ammonium chloride Metformin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amoxapine Amoxapine may decrease the hypoglycemic avcion of Metformin. Amoxicillin Metformin may decrease the excretion mecanjsmo of Amoxicillin acclon could result in cffepime higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level. Amphotericin Cedepime Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.

Ampicillin Metformin may decrease the excretion rate of Ampicillin which could result in a higher serum level. Amrinone Metformin may decrease the excretion rate of Amrinone which could result in a higher serum level. Anagliptin The risk or severity of hypoglycemia can be increased when Metformin is combined with Anagliptin. Ancestim Metformin may decrease the excretion rate of Ancestim which could result in a higher serum level.

Antipyrine Antipyrine may decrease the excretion rate of Metformin which could result in a higher serum level. Antrafenine Antrafenine may decrease the excretion rate of Metformin which could result in a higher serum level. Apalutamide The serum concentration of Metformin can be increased when it is combined with Apalutamide. Apramycin Apramycin may decrease the excretion rate of Metformin which could result in a higher serum level.

Apremilast Metformin may decrease the excretion rate of Apremilast which could result in a higher serum level.